Canaccord Genuity Group Boosts Hims & Hers Health (NYSE:HIMS) Price Target to $68.00

Hims & Hers Health (NYSE:HIMS - Get Free Report) had its price target lifted by investment analysts at Canaccord Genuity Group from $38.00 to $68.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Canaccord Genuity Group's price objective indicates a potential upside of 38.51% from the stock's previous close.

Several other research analysts also recently commented on HIMS. TD Cowen reissued a "buy" rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Morgan Stanley downgraded shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their price objective for the stock from $42.00 to $60.00 in a report on Tuesday. Bank of America downgraded shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and dropped their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a "buy" rating in a report on Monday, January 6th. Finally, Citigroup downgraded shares of Hims & Hers Health from a "neutral" rating to a "sell" rating and lifted their price objective for the stock from $24.00 to $25.00 in a report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $28.53.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $17.32 during trading hours on Wednesday, hitting $49.10. The stock had a trading volume of 88,092,811 shares, compared to its average volume of 17,942,531. The company has a 50 day simple moving average of $34.66 and a two-hundred day simple moving average of $25.48. Hims & Hers Health has a one year low of $9.25 and a one year high of $72.98. The firm has a market capitalization of $10.73 billion, a price-to-earnings ratio of 111.58 and a beta of 1.35.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the transaction, the chief executive officer now owns 97,687 shares of the company's stock, valued at $5,692,221.49. The trade was a 56.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Melissa Baird sold 85,561 shares of Hims & Hers Health stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $31.01, for a total value of $2,653,246.61. Following the completion of the sale, the chief operating officer now owns 630,986 shares of the company's stock, valued at $19,566,875.86. The trade was a 11.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,184,611 shares of company stock valued at $40,338,442 in the last quarter. 17.71% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently bought and sold shares of HIMS. Mackenzie Financial Corp grew its stake in shares of Hims & Hers Health by 44.6% during the 4th quarter. Mackenzie Financial Corp now owns 29,096 shares of the company's stock valued at $704,000 after purchasing an additional 8,977 shares during the period. Public Employees Retirement System of Ohio bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $99,000. Neo Ivy Capital Management grew its stake in shares of Hims & Hers Health by 145.4% during the 4th quarter. Neo Ivy Capital Management now owns 166,734 shares of the company's stock valued at $4,031,000 after purchasing an additional 98,798 shares during the period. PharVision Advisers LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $234,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Hims & Hers Health by 31.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,156 shares of the company's stock valued at $8,225,000 after purchasing an additional 81,495 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.